Britain Is Growing Tiny Human Organs in a £22m Push to Replace Animal Testing

Inside Britain’s Plan to Test New Medicines on Human Tissue

Tiny Human Organs Could Help Britain Break Its Reliance on Animal Tests

Britain is investing £22 million in miniature human organs, beating heart tissue, lab-grown ear models and artificial intelligence as it tries to reduce its reliance on animal testing. The programme could change how new medicines are selected, tested and eventually prescribed to patients.

At its centre is a new £20 million Pre-clinical Translational Models Hub in Cambridge. Scientists will grow simplified versions of human guts, tumours and brains from cells donated by NHS patients, creating living models that retain important features of each person’s biology.

Human Biology Moves Into the Laboratory

These models are known as organoids. They are not complete organs and cannot think, feel or function independently, but they can recreate important parts of an organ’s structure, disease behaviour and response to treatment.

That distinction matters. A drug tested on an animal may behave differently when it encounters human cells, while two people with the same diagnosis can also respond differently because the biological cause of their illness is not identical.

Patient-derived organoids could allow scientists to expose several versions of the same disease to a potential medicine. Researchers may then see whether the treatment reverses harmful changes in every sample, works only for a particular group or appears unlikely to help anyone.

The first work will include inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis. Other researchers are expected to develop tumour models for cancer research and electrically active brain organoids for neurological conditions.

Cambridge Becomes the National Hub

The new facility will be based on the Cambridge Biomedical Campus and draw on a research community of around 60 principal investigators. Its leadership will include scientists from the MRC Laboratory of Molecular Biology and the Wellcome Sanger Institute, with NHS, university and pharmaceutical partners close by.

Its task is larger than growing impressive objects in laboratory dishes. The hub must create models that are reproducible, scalable and validated against clinical data before researchers and drug companies can rely on them.

Scientists across Britain will eventually be able to access its models, patient samples, data and specialist expertise. Artificial-intelligence tools will also be developed to interrogate complex biological information and help researchers identify promising drug targets.

The hub itself will not conduct animal experiments. Its models may, however, be compared with existing animal data during validation, underlining that this is a staged scientific transition rather than an instant prohibition.

Nine Projects Target Tests Still Using Animals

The remaining funding—up to £2 million from Innovate UK—will support nine early-stage projects focused on cardiovascular safety and pharmacokinetics, the study of how medicines move through the body.

VivoSphere UK is developing lab-grown heart-like tissues that could reveal dangerous cardiac side effects before a treatment advances. BiomimX is building miniature living heart tissue to show how medicines affect beating and pumping, while CamGene Therapeutics is creating human ear models for hearing-loss research.

CN Bio is developing interconnected human models and simulations to predict how drugs behave inside people. Other projects will use AI to predict drug movement and the distribution of lipid nanoparticles, which are increasingly important delivery systems for modern medicines.

Several projects specifically target safety studies that still use dogs and non-human primates. Biofoundry Energy says its platform is aimed at reducing dedicated cardiovascular studies involving those animals by more than 50 per cent.

Britain Still Conducts Millions of Procedures

Great Britain recorded 2.54 million regulated scientific procedures involving living animals in 2025. That was a 3.8 per cent annual fall and the lowest total recorded under the current regulatory system, although the figure counts procedures rather than individual animals.

Mice, fish, birds and rats accounted for 95 per cent of all procedures. Around 17,300 experimental procedures involved specially protected species—cats, dogs, horses and non-human primates—with dogs and primates predominantly used for regulatory purposes.

The new investment will not replace every one of those procedures. Complex whole-body effects, interactions between organs and long-term responses can remain difficult to reproduce using isolated tissue, while regulators must be convinced that each alternative is reliable enough to protect patients.

That validation barrier may prove harder than growing the tissue itself. A laboratory model can be scientifically promising without yet being standardised, reproducible across different facilities or accepted as evidence by British and international regulators.

The Prize Is Bigger Than Animal Welfare

Reducing animal use is the clearest ethical goal, but the economic and medical stakes are just as significant. Britain’s life-sciences sector generates about £147 billion in turnover and employs roughly 360,000 people, making better pre-clinical testing a potential source of investment as well as scientific progress.

Drug development is slow and expensive partly because potential treatments can fail after years of work. Human-relevant models could identify ineffective or dangerous candidates earlier, allowing money and research time to move towards stronger prospects.

The same technology could also advance personalised medicine. If an organoid grown from a patient’s cells responds to one treatment but not another, clinicians may eventually gain more evidence about which option is most likely to work before exposing that person to repeated trial and error.

What Happens Next

The Cambridge hub is expected to begin work by November 2026 and receive funding for up to 42 months, subject to approval of its full business case. The nine Innovate UK awards form the first phase of a two-stage competition, with the strongest projects potentially progressing towards real-world deployment.

Britain has already committed to replacing animal tests more quickly where validated alternatives exist, including targets covering skin and eye irritation, skin sensitisation and some biological medicines. The decisive question is now whether miniature human tissues can move from impressive laboratory science to trusted tools used throughout the pharmaceutical industry.

If they can, the most important result will not merely be fewer animals entering laboratories. It will be a drug-development system built around the biology medicines are ultimately supposed to treat: human biology.